ReviewTranslational gastroenterology and hepatology2026
Eosinophilic and mastocytic gastrointestinal diseases: current knowledge and controversy in histopathologic diagnosis.
Review in Translational gastroenterology and hepatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Eosinophilic and mastocytic gastrointestinal (GI) diseases represent a spectrum of immune-mediated inflammatory disorders characterized by abnormal accumulation of eosinophils or mast cells in the GI tract. This review summarizes current knowledge on epidemiology, pathogenesis, histopathologic features, diagnostic challenges, and ongoing controversies across three major domains: eosinophilic esophagitis (EoE), non-EoE eosinophilic gastrointestinal diseases (EGID), and mastocytic GI diseases. Although these entities are increasingly recognized in clinical practice, their diagnosis remains challenging because clinical manifestations are often nonspecific and overlap with other inflammatory and functional GI disorders. Consequently, substantial uncertainties persist regarding diagnostic criteria and clinical relevance of certain histologic patterns. For non-EoE EGIDs, histologic diagnosis is particularly complicated by wide regional variation in normal eosinophil densities, the lack of universally accepted diagnostic cutoffs in adults, and limited correlation between tissue eosinophil burden and symptom severity. In mastocytic GI diseases, additional challenges include distinguishing reactive mast cell hyperplasia from clonal mastocytosis and interpreting proposed entities such as mastocytic enterocolitis, whose clinical significance remains controversial. Given these limitations, histopathologic evaluation of GI biopsies plays a central role in disease recognition and classification. This review emphasizes practical aspects of tissue interpretation, including site-specific reference ranges, proposed diagnostic thresholds, characteristic morphologic patterns, ancillary immunohistochemical and molecular studies, and common interpretive pitfalls encountered in routine practice. Recognizing these diseases ultimately requires careful clinicopathologic correlation, integrating histologic findings with clinical, endoscopic, and molecular data. Improved standardization of diagnostic criteria and clearer definition of histologic thresholds remain critical unmet needs for both pathologists and clinicians managing these complex disorders.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.